|
Getting ready for Chicago
|
With a little less than a month to go, the ACO team is getting ready for HIVR4P 2016 happening in Chicago on October 17 – 21, 2016. We will be hosting a satellite session at the upcoming conference entitled, Beyond Viral Neutralization, which will bring the scientific community together to discuss the latest developments in the expanding field of non-neutralizing, effector function competent (nNeFC) anti-HIV-1 antibodies. We will also be hosting an invitation-only networking breakfast for Canadian researchers. For more information on ACO activities at HIVR4P, please visit our website. A full list of independently organized sessions happening at the conference is available on the HIVR4P 2016 website. We look forward to connecting with you in Chicago!
|
| |
| |
|
The ACO continues to feature Canadian researchers who are making an impact in HIV vaccine research and development. At the CAHR Conference held in Winnipeg, Manitoba (May 2016), HIV researcher Felicién Moukambi, talked to us about his research on the depletion of Tfh cells in SIV-infected macaques. Felicién works at the laboratory of Dr. Jérôme Estaquier at the Centre de recherche du CHU de Québec. Watch the video
|
| |
| |
|
CIHR’S Q&A Webinars
September 22 and 26, 2016
The Canadian Institutes of Health Research (CIHR) is holding a series of English and French Question and Answer webinars: Foundation Grant: 2016 (stage 1 application beginning Thursday, September 22) and Project Grant: Fall 2016 (application beginning Monday, September 26). These webinars afford both applicants and research administrators the opportunity to pose any outstanding questions they may have about the stage 1 application.
More information
|
| |
|
A New HIV Vaccine? Cambridge Firm’s Leading Role in Research Project
Cambridge News, September 8, 2016
A Cambridge company is playing a leading role in a consortium which is looking at a new way to develop a vaccine for HIV. Antibody firm Kymab has teamed up with The Scripps Research Institute (TSRI) of San Diego, California, and the International AIDS Vaccine Initiative (IAVI) for a research project, which tested the first step in an approach to develop effective vaccines against the range of HIV variants existing worldwide.
READ MORE
New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies
PR Newswire, September 8, 2016
"It's early work, but we're trying to rewrite some rules of vaccine development to overcome the extraordinary challenges of HIV," says William Schief, TSRI Professor and Director of Vaccine Design for IAVI's Neutralizing Antibody Center (NAC) at TSRI. "In a collaborative effort we have reached critical milestones, including the first proof ever that immunization with designer proteins can produce broadly neutralizing antibodies against HIV. The new results strongly support further developing these approaches toward testing in clinical studies."
READ MORE
AIDS Epidemic Worse Than Before, Says Mark Feinberg
The Hindu, September 12, 2016
On the sidelines of the India Africa Health Sciences Meet, Mark Feinberg, Chief Executive Officer of the International AIDS Vaccine Initiative, spoke to Vidya Krishnan about the lack of urgency weakening global HIV interventions. Having spent nearly three decades in HIV research, Dr. Feinberg said the AIDS epidemic was worse than ever but it had become less visible, leading governments to think that the problem had been solved.
READ MORE
|
|
New Research
Antibody-Depedent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers.
AIDS Res Hum Retroviruses. 2016 Sep 7. [Epub ahead of print]
Isitman G, Lisovsky I, Tremblay-McLean A, Kovacs C, Harris M, Routy JP, Bruneau J, Wainberg MA, Tremblay C, Bernard NF.
|
|
NKG2D Acts as a Co-receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity.
AIDS Res Hum Retroviruses. 2016 Sep 7. [Epub ahead of print]
Parsons MS, Richard J, Lee WS, Vanderven H, Grant MD, Finzi A, Kent SJ.
|
|
Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
J Control Release. 2016 Aug 28;236:22-30. doi: 10.1016/j.jconrel.2016.06.019. Epub 2016 Jun 11
Ding Y, Liu J, Lu S, Igweze J, Xu W, Kuang D, Zealey C, Liu D, Gregor A, Bozorgzad A, Zhang L, Yue E, Mujib S, Ostrowski M, Chen P.
|
| |
|
|
|
Conferences
|
|
October 11 to 14, 2016
34th Annual Symposium on Nonhuman Primate Models for AIDS
New Orleans, USA
|
|
October 17 to 20, 2016
HIV Research for Prevention
Chicago, USA
|
|
October 24 to 26, 2016
OHTN Conference Series: Conference 1 – Closing the Gaps in the Care Cascade
Toronto, CA
|
|
November 21 to 22, 2016
OHTN Conference Series: Conference 2 – Stopping the Syndemics that Drive HIV
Toronto, CA
|
|
December 3 to 4, 2016
National HIV PrEP Summit
San Francisco, USA
|
|
December 6 to 8, 2016
12th Canadian Immunization Conference (CIC 2016)
Ottawa, CA
|
|
December 11 to 15, 2016
Antibody Engineering & Therapeutics
San Diego, USA
See full list of conferences
|
|
|
| |
You are receiving this email because you registered to receive news updates from the ACO
or you are a member of a
CHVI-funded
project team.
|
| |
| |
| |
| |
|
Annual Update
|
|
Want to know what the ACO has been up to? The annual report offers highlights of ACO activities over the past fiscal year.
|
|
|
Scan the QR code to read the annual update on your mobile, or view it on your desktop. French version available upon request, email aco@icid.com.
|
| |
| |
| |
| |
| |
| |
|
About Us
|
|
The ACO was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
| |
| |
| |
| |
| |
| |
| |
|
Connect With Us:
|
|
ACO at
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
|
| |
| |
| |
| |
| |
|
